Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.37 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.37 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.37 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | DDO | Q99489 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29722486 | 1.00 | CA3 (0.52) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL319589 | 0.81 | CA3 (0.46) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL7772653 | 0.81 | CA3 (0.46) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL30586687 | 0.81 | CA3 (0.46) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL39406 | 0.78 | CES2 (0.43) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL29395656 | 0.78 | CES2 (0.43) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL10269424 | 0.77 | MAOA (0.40) | ESR2PTGS1KDM4ENPC1 | |
| SCHEMBL408067 | 0.76 | ACHE (0.41) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL29426963 | 0.76 | ACHE (0.41) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL3791591 | 0.75 | TYR (0.42) | CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118515534-B | Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof | 华南理工大学 | 2024-11-05 | — | — | CN | claimed |
| CN-118515534-A | Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof | 华南理工大学 | 2024-08-20 | — | — | CN | claimed |
| CN-116731315-B | Boron-containing phthalonitrile resin and preparation method and application thereof | 中国科学院化学研究所 | 2024-06-21 | — | — | CN | claimed |
| CN-116731315-A | Boron-containing phthalonitrile resin and preparation method and application thereof | 中国科学院化学研究所 | 2023-09-12 | — | — | CN | claimed |
| CN-111146496-B | Polymer electrolyte and lithium ion battery containing same | 珠海冠宇电池股份有限公司 | 2021-07-13 | — | — | CN | claimed |
| CN-111146496-A | Polymer electrolyte and lithium ion battery containing same | 珠海冠宇电池有限公司 | 2020-05-12 | — | — | CN | claimed |
| EP-4213843-B1 | MODIFIED IMIDAZOPYRIDINES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4347571-B1 | TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. | HOFFMANN LA ROCHE (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-12599676-B2 | Cytotoxic imidazo[1,2-A]pyridine compounds and their use in therapy | MyricX Pharma Limited (GB) | 2026-04-14 | — | — | US | disclosed |
| US-12590106-B2 | Spiromacrocyclic orexin 2 receptor agonists | H. LUNDBECK A/S (DK) | 2026-03-31 | — | — | US | disclosed |
| US-12570650-B2 | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders | AURIGENE ONCOLOGY LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-12559491-B2 | Modified imidazopyridines as glucosylceramide synthase inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260048136-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | MYRICX PHARMA LTD (GB) | 2026-02-19 | — | — | US | disclosed |
| EP-1706403-A2 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | K.U.Leuven Research & Development (BE) | 2006-10-04 | — | — | EP | disclosed |
| US-20060100262-A1 | Tetracyclic indole derivatives as antiviral agents | ISTITUTO DI RICHERCHEDI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IRMB) (IT) | 2006-05-11 | — | — | US | disclosed |
| WO-2006046030-A2 | TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2006-05-04 | — | — | WO | disclosed |
| US-20050222198-A1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | K.U. LEUVEN RESEARCH & DEVELOPMENT, GERHARD PUERSTINGER AND GILEAD SCIENCES, INC. | 2005-10-06 | — | — | US | disclosed |
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005063744-A2 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559491-B2 | Modified imidazopyridines as glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | CA3 1721/4885CA6 716/4885CA5A 846/4885 |
| US-20060100262-A1 | Tetracyclic indole derivatives as antiviral agents | IDO1, ZC3HAV1, IDO2 | CA3 3112/4885CA6 2107/4885CA5A 1632/4885 |
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | CA3 3714/4885CA6 3810/4885CA5A 3072/4885 |
| US-20260048136-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | SLC7A1, FLT3, ABL1 | CA3 3504/4885CA6 1485/4885CA5A 2260/4885 |
| US-12590106-B2 | Spiromacrocyclic orexin 2 receptor agonists | HCRTR2, HCRTR1, OXER1 | CA3 1783/4885CA6 2958/4885CA5A 1571/4885 |
| US-12599676-B2 | Cytotoxic imidazo[1,2-A]pyridine compounds and their use in therapy | ABL1, FLT3, MTX2 | CA3 3535/4885CA6 2350/4885CA5A 2677/4885 |
| US-20050222198-A1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | CYP3A5, TPMT, TYMP | CA3 3169/4885CA6 692/4885CA5A 249/4885 |
| US-12570650-B2 | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders | SMARCC1, SMARCC2, SMARCA1 | CA3 2530/4885CA6 206/4885CA5A 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.